Hopital Henri Mondor - 1 rue Gustave Eiffel

The medical center is at the forefront of oncology research, particularly in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. The ongoing study on sotorasib targets patients with KRAS p.G12C mutations, aiming to evaluate tumor response and identify biomarkers associated with resistance to treatment.

• KRAS p.G12C Mutations
• Tumor Response Evaluation
• Biomarker Identification

This research contributes significantly to personalized cancer therapies, offering insights into genetic factors that influence treatment efficacy.

Specializing in nephrology and immunology, the center conducts pivotal research on ANCA vasculitis and end-stage renal disease (ESRD). The study investigates the effects of discontinuing immunosuppressive therapy in ESRD-AAV patients, aiming to improve survival outcomes without severe adverse events.

• Immunosuppressive Therapy Discontinuation
• ANCA Vasculitis Management
• Renal Disease Outcomes

This research is crucial in redefining treatment protocols for patients with complex autoimmune and renal conditions, enhancing quality of life and long-term health.

The center excels in hematology, focusing on advanced stages of chronic myelogenous leukemia (CML). The study explores the efficacy of combining ponatinib and 5-azacitidine in patients with accelerated phase or myeloid blast crisis, aiming to improve overall survival rates.

• Combination Therapy Efficacy
• Survival Rate Improvement
• Advanced CML Management

This research is pivotal in developing new therapeutic strategies for aggressive forms of leukemia, offering hope for improved patient outcomes.